본문으로 건너뛰기
← 뒤로

[Medical tumor therapy for head and neck cancer: between standardization and personalization].

1/5 보강
HNO 📖 저널 OA 10.4% 2021: 1/4 OA 2022: 1/5 OA 2023: 0/1 OA 2024: 3/4 OA 2025: 2/4 OA 2026: 7/13 OA 2021~2026 2026 Vol.74(2) p. 97-109 OA
Retraction 확인
출처

Laban S

📝 환자 설명용 한 줄

In the field of systemic cancer therapy for head and neck neoplasms, new approvals have led to several changes in treatment standards, primarily in the palliative situation.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Laban S (2026). [Medical tumor therapy for head and neck cancer: between standardization and personalization].. HNO, 74(2), 97-109. https://doi.org/10.1007/s00106-025-01591-7
MLA Laban S. "[Medical tumor therapy for head and neck cancer: between standardization and personalization].." HNO, vol. 74, no. 2, 2026, pp. 97-109.
PMID 40261344 ↗

Abstract

In the field of systemic cancer therapy for head and neck neoplasms, new approvals have led to several changes in treatment standards, primarily in the palliative situation. At the same time, molecular biomarkers have been established that can contribute to therapeutic decision-making in addition to clinical factors. These developments are summarized, and potential strategies to resolve the tension between standardization and personalization are described. Results from randomized phase III studies with therapeutic antibodies targeting the PD1/PD-L1 axis in combination with definitive chemoradiation are described and discussed. Finally, inspired by the press release about the positive results of the neoadjuvant KEYNOTE-689 trial in locoregionally advanced resectable disease, potential measures and suggestions for integrating neoadjuvant immunotherapy into clinical routine are discussed.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기